NO20081133L - Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer - Google Patents

Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer

Info

Publication number: NO20081133L
Authority: NO; Norway
Prior art keywords: tieno; carbonitriles; pyridine; protein kinase; kinase inhibitors
Prior art date: 2005-09-27

Application number

NO20081133A

Other languages

English (en)

Norwegian (no)

Inventor

Derek Cecil Cole

Magda Asselin

Diane Harris Boschelli

Biqi Wu

Ana Carolina Barrios Sosa

Lawrence Nathan Tumey

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-27

Filing date

2008-03-04

Publication date

2008-04-25

2008-03-04 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-04-25 Publication of NO20081133L publication Critical patent/NO20081133L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20081133A 2005-09-27 2008-03-04 Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer NO20081133L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72082105P	2005-09-27	2005-09-27
PCT/US2006/037502 WO2007038519A1 (en)	2005-09-27	2006-09-27	Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20081133L true NO20081133L (no)	2008-04-25

Family

ID=37603099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081133A NO20081133L (no)	2005-09-27	2008-03-04	Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer

Country Status (16)

Country	Link
US (1)	US20070082880A1 (ru)
EP (1)	EP1937690A1 (ru)
JP (1)	JP2009511439A (ru)
KR (1)	KR20080059184A (ru)
CN (1)	CN101273047A (ru)
AR (1)	AR056200A1 (ru)
AU (1)	AU2006294726A1 (ru)
BR (1)	BRPI0616758A2 (ru)
CA (1)	CA2623228A1 (ru)
GT (1)	GT200600434A (ru)
NO (1)	NO20081133L (ru)
PE (1)	PE20070619A1 (ru)
RU (1)	RU2008108619A (ru)
TW (1)	TW200745137A (ru)
WO (1)	WO2007038519A1 (ru)
ZA (1)	ZA200802690B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7276519B2 (en) *	2002-11-25	2007-10-02	Wyeth	Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200821318A (en) *	2006-09-26	2008-05-16	Wyeth Corp	Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
US20090118276A1 (en) *	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2011075559A1 (en) *	2009-12-18	2011-06-23	Glaxo Wellcome Manufacturing Pte Ltd.	Novel compounds
WO2012030894A1 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP3590925B1 (en)	2010-09-17	2022-03-30	Purdue Pharma L.P.	Pyridine compounds and the uses thereof
CN103459371A (zh) *	2011-04-02	2013-12-18	中国人民解放军军事医学科学院毒物药物研究所	芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途
US9801863B2 (en)	2012-04-16	2017-10-31	Case Western Reserve University	Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
HUE037262T2 (hu)	2012-04-16	2018-08-28	Univ Case Western Reserve	Készítmények és 15-PGDH aktivitás modulálási módszerek
CA2927730A1 (en)	2013-10-15	2015-05-07	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
JP2019512491A (ja) *	2016-03-11	2019-05-16	エーシー・イミューン・エス・アー	診断及び療法のための二環式化合物
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
US11718589B2 (en)	2017-02-06	2023-08-08	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase
BR112021009832A2 (pt)	2018-11-21	2021-08-17	Case Western Reserve University	composições e métodos de modulação da atividade da desidrogenase de cadeia curta
CN113874015B (zh) *	2018-12-21	2024-05-24	细胞基因公司	Ripk2的噻吩并吡啶抑制剂
US20240400591A1 (en) *	2021-08-10	2024-12-05	Jacobio Pharmaceuticals Co., Ltd.	Compounds targeting mutant of p53
CN114957280B (zh) *	2021-12-31	2024-09-17	成都赜灵生物医药科技有限公司	噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
PL340589A1 (en) *	1997-11-11	2001-02-12	Pfizer Prod Inc	Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
US5948911A (en) *	1998-11-20	1999-09-07	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
GB9906566D0 (en) *	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
AU6578900A (en) *	1999-07-07	2001-01-30	Astrazeneca Uk Limited	Quinazoline derivatives
ATE300303T1 (de) *	2000-03-06	2005-08-15	Astrazeneca Ab	Verwendung von quinazolinderivate als inhibitoren der angiogenese
EP1287001B1 (en) *	2000-06-06	2004-09-29	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) *	2000-06-28	2002-01-10	Luzzio Michael Joseph	Thiophene derivatives useful as anticancer agents
AU2002345792A1 (en) *	2001-06-21	2003-01-08	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
ES2318141T3 (es) *	2002-06-06	2009-05-01	Boehringer Ingelheim Pharmaceuticals Inc.	Compuestos de amida de acido 3-amino-tieno(2,3-b)piridina-2-carboxilico y procedimiento de preparacion y sus usos.
US7276519B2 (en) *	2002-11-25	2007-10-02	Wyeth	Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) *	2002-11-25	2005-01-14	Wyeth Corp	COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7674907B2 (en) *	2004-07-23	2010-03-09	Amgen Inc.	Furanopyridine derivatives and methods of use
AU2005284796A1 (en) *	2004-09-15	2006-03-23	Janssen Pharmaceutica, N.V.	Thiazolopyridine kinase inhibitors
KR101378716B1 (ko) *	2005-05-20	2014-04-10	메틸진 인코포레이티드	Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제

2006
- 2006-09-25 PE PE2006001155A patent/PE20070619A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104166A patent/AR056200A1/es unknown
- 2006-09-26 TW TW095135537A patent/TW200745137A/zh unknown
- 2006-09-27 RU RU2008108619/04A patent/RU2008108619A/ru not_active Application Discontinuation
- 2006-09-27 JP JP2008533522A patent/JP2009511439A/ja not_active Withdrawn
- 2006-09-27 AU AU2006294726A patent/AU2006294726A1/en not_active Abandoned
- 2006-09-27 GT GT200600434A patent/GT200600434A/es unknown
- 2006-09-27 CN CNA2006800357351A patent/CN101273047A/zh active Pending
- 2006-09-27 BR BRPI0616758-6A patent/BRPI0616758A2/pt not_active IP Right Cessation
- 2006-09-27 CA CA002623228A patent/CA2623228A1/en not_active Abandoned
- 2006-09-27 WO PCT/US2006/037502 patent/WO2007038519A1/en not_active Ceased
- 2006-09-27 US US11/527,996 patent/US20070082880A1/en not_active Abandoned
- 2006-09-27 KR KR1020087008455A patent/KR20080059184A/ko not_active Withdrawn
- 2006-09-27 EP EP06804164A patent/EP1937690A1/en not_active Withdrawn
2008
- 2008-03-04 NO NO20081133A patent/NO20081133L/no not_active Application Discontinuation
- 2008-03-26 ZA ZA200802690A patent/ZA200802690B/xx unknown

Also Published As

Publication number	Publication date
WO2007038519A1 (en)	2007-04-05
EP1937690A1 (en)	2008-07-02
CN101273047A (zh)	2008-09-24
BRPI0616758A2 (pt)	2011-06-28
GT200600434A (es)	2007-05-28
KR20080059184A (ko)	2008-06-26
PE20070619A1 (es)	2007-07-02
CA2623228A1 (en)	2007-04-05
AR056200A1 (es)	2007-09-26
AU2006294726A1 (en)	2007-04-05
TW200745137A (en)	2007-12-16
RU2008108619A (ru)	2009-11-10
JP2009511439A (ja)	2009-03-19
US20070082880A1 (en)	2007-04-12
ZA200802690B (en)	2009-08-26

Publication	Publication Date	Title
NO20081133L (no)	2008-04-25	Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
NO20045677L (no)	2005-02-28	Inhibitorer av JAK- og CDK2-proteinkinaser
EA200801301A1 (ru)	2009-02-27	ИНГИБИТОРЫ АКТИВНОСТИ Akt
NO20074666L (no)	2007-11-09	Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
GEP20084367B (en)	2008-05-13	Diazepinoindole derivatives as kinase inhibitors
NO20055496L (no)	2006-02-14	Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
WO2007079164A3 (en)	2007-09-27	Protein kinase inhibitors
NO20092668L (no)	2009-09-21	5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors
NO20070731L (no)	2007-02-19	Heterocykliske forbindelser.
NO20075987L (no)	2008-01-11	Bisykliske derviater som p38-kinaseinhibitorer
CY1112253T1 (el)	2015-12-09	Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης
WO2007044084A3 (en)	2009-04-16	Heterocyclic inhibitors of mek and methods of use thereof
WO2004087699A3 (en)	2004-12-09	Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en)	2004-12-09	Thiazoles useful as inhibitors of protein kinases
WO2007023110A3 (en)	2007-05-03	P38 map kinase inhibitors and methods for using the same
GEP20105054B (en)	2010-07-26	Imidazoquinolines as lipid kinase inhibitors
NO20081349L (no)	2008-05-07	Pyrrolopyrimidinderivater som Syk-inhibitorer
EA201070395A1 (ru)	2010-10-29	Ингибиторы polo-подобных киназ
NO20064000L (no)	2006-09-22	Heteroarylkoblede pyrazoloderivater
NO20082476L (no)	2008-06-24	Bicykliske forbindelser med kinaseinhiberende aktivitet
BRPI0507852A (pt)	2007-07-10	2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
PT1689391E (pt)	2009-06-19	Derivados 5-fenil-4-metil-tiazol-2-il-amina como inibidores de enzimas fosfatidilinositol 3 quinase (pi3) para o tratamento de doenças inflamatórias das vias respiratórias
MY169791A (en)	2019-05-15	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2009006389A3 (en)	2009-05-07	Pyrimidine derivatives useful as raf kinase inhibitors
NO20082594L (no)	2008-06-10	Pyrimidinylbenzotiofenforbindelser

Legal Events

Date	Code	Title	Description
2010-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application